USPSTF Still Advises Against COPD Screening for Asymptomatic Adults
Task force concludes with moderate certainty that there is no net benefit for screening asymptomatic adults for COPD
Chronic Obstructive Pulmonary Disease
Fluticasone Furoate/Umeclidinium/Vilanterol Therapy and COPD Exacerbations
Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA?
A New Basis for Predicting Future COPD Exacerbations During the Pandemic
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
E-Cigarette Use Associated With Increased Odds of Asthma and COPD
Researchers evaluated the relationship between e-cigarettes and obstructive pulmonary diseases, taking into account age, gender, ethnicity, and body mass index.
Nebulized Revefenacin for COPD Appears More Effective in Women vs Men
Researchers conducted subgroup analysis of revenfenacin phase 3 trial data to assess health status improvements in women vs men with moderate to severe COPD.
FDA Clears Add-On Device That Turns MDIs Into Smart Inhalers
The device is attached to the top of the canister of the patient’s inhaler and works together with the mobile app to monitor and provide feedback.
Generic Version of Perforomist Now Available
The first authorized generic version of Perforomist® (formoterol fumarate inhalation solution; Mylan Specialty L.P.) 20mcg/2mL has been made available by Teva Pharmaceuticals.
Asthma, COPD Do Not Increase Mortality Risk in Patients With COVID-19
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
Single-Inhaler Triple Therapy Reduces Composite AE Risk vs Dual Therapy in COPD
Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations.
Effect of Blood Eosinophil Counts on COPD Clinical Outcomes
Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts.
